ZERIT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zerit, and what generic alternatives are available?
Zerit is a drug marketed by Bristol and Bristol Myers Squibb and is included in three NDAs.
The generic ingredient in ZERIT is stavudine. There are fourteen drug master file entries for this compound. Additional details are available on the stavudine profile page.
Summary for ZERIT
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 119 |
Patent Applications: | 5,112 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ZERIT |
What excipients (inactive ingredients) are in ZERIT? | ZERIT excipients list |
DailyMed Link: | ZERIT at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ZERIT
US Patents and Regulatory Information for ZERIT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol | ZERIT | stavudine | CAPSULE;ORAL | 020412-001 | Jun 24, 1994 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bristol Myers Squibb | ZERIT XR | stavudine | CAPSULE, EXTENDED RELEASE;ORAL | 021453-001 | Dec 31, 2002 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bristol | ZERIT | stavudine | CAPSULE;ORAL | 020412-004 | Jun 24, 1994 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZERIT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bristol | ZERIT | stavudine | CAPSULE;ORAL | 020412-003 | Jun 24, 1994 | ⤷ Try a Trial | ⤷ Try a Trial |
Bristol | ZERIT | stavudine | CAPSULE;ORAL | 020412-004 | Jun 24, 1994 | ⤷ Try a Trial | ⤷ Try a Trial |
Bristol | ZERIT | stavudine | CAPSULE;ORAL | 020412-001 | Jun 24, 1994 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for ZERIT
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Bristol-Myers Squibb Pharma EEIG | Zerit | stavudine | EMEA/H/C/000110 Hard capsulesZerit is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adult patients and paediatric patients (over the age of three months) only when other antiretrovirals can not be used. The duration of therapy with Zerit should be limited to the shortest time possible.Powder for oral solutionZerit is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adult patients and paediatric patients (from birth) only when other antiretrovirals can not be used. The duration of therapy with Zerit should be limited to the shortest time possible. |
Withdrawn | no | no | no | 1996-05-08 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ZERIT
See the table below for patents covering ZERIT around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Portugal | 86346 | METODO DE TRATAMENTO MEDIANTE A ADMINISTRACAO DE 3'-DESOXITIMIDINENO-2' (3'-DESOXI-2',3'-DIDESIDROTIMIDINA) A ANIMAIS DE SANGUE QUENTE INFECTADOS COM RETROVIRUS | ⤷ Try a Trial |
Israel | 84790 | ⤷ Try a Trial | |
Egypt | 19157 | The use of 3- deoxythmiding-2'-ene(3'-deoxy 2-3dedehydrothymidine) in treating patients infected with retroviruses | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ZERIT
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0383472 | 96C0040 | Belgium | ⤷ Try a Trial | PRODUCT NAME: STAVUDINE; NAT. REGISTRATION NO/DATE: EU/1/96/009/001-009 19960509; FIRST REGISTRATION: |
0273277 | C960024 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: STAVUDINE; REGISTRATION NO/DATE: EU/1/96/009/001 - EU/1/96/009/009 19960508 |
0273277 | 96C0039 | Belgium | ⤷ Try a Trial | PRODUCT NAME: STAVUDINE; REGISTRATION NO/DATE: EU/1/96/009/001 19960508 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |